Send to

Choose Destination
Transcription. 2018;9(1):17-29. doi: 10.1080/21541264.2017.1329684. Epub 2017 Oct 4.

linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer.

Author information

a The RNA Institute, University at Albany, State University of New York , Albany , NY , USA.
b MTA TTK Lendület Cancer Biomarker Research Group, Hungarian Academy of Sciences , Budapest , Hungary.
c Semmelweis University 2nd Dept. of Pediatrics , Budapest , Hungary.
d Investigative medicine Program , Yale University School of Medicine , New Haven , CT , USA.


LncRNAs are novel noncoding RNAs involved in the epigenetic regulation of gene expression by recruiting ribonucleoprotein complexes to specific genomic loci to initiate histone methylation and/or other chromatin modifications. LncRNAs themselves function as tumor suppressors or oncogenes, depending on the gene regulatory networks they govern. We identified lnc00673 (ERRLR01) as a marker of overall survival (OS) in breast cancer patients. Specifically, ERRLR01 levels were elevated in triple-negative breast cancer (TNBC) as compared with Luminal-A, Luminal-B, and HER2 breast cancer subtypes. ERRLR01 levels were also inversely correlated with breast cancer survival across all breast cancer patients. Upon stratification, OS in ERα- tumors correlated with negative overall survival, while in ERα+ tumors, ERRLR01 correlated with positive outcomes. This suggests ERRLR01 is modulated by hormone signaling in breast cancer. Gene-network analysis revealed ERRLR01 correlated with distinct pathways including "epithelial development" and "cellular differentiation." These data suggest ERRLR01 operates as an oncogene in TNBC, as well as a biomarker in breast cancer patients.


ERRLR01; breast cancer; estrogen signaling; hormone-regulation; lncRNA; survival outcomes

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center